These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A comparison of bronchodilator responses to albuterol delivered by ultrasonic versus jet nebulization in moderate to severe asthma.
    Author: Pallares DE, Pilarski BR, Rodriguez JL, Leickly FE.
    Journal: Ann Allergy Asthma Immunol; 1996 Oct; 77(4):292-7. PubMed ID: 8885806.
    Abstract:
    BACKGROUND: Nebulization of beta-agonists is preferred as a mode of treatment in moderate to severe asthma. Few studies, however, have compared its use in this population using an ultrasonic versus a jet nebulizer. OBJECTIVE: The purpose of the study was to compare bronchodilator responses to albuterol between an ultrasonic and a jet nebulizer in moderate to severe asthma. METHODS: Fifteen stable, moderately to severely asthmatic patients were randomized to receive the ultrasonic or jet nebulizer for 2 weeks. They were then crossed over for an additional 2 weeks. Albuterol was the agent used. The bronchodilator response was measured at baseline, and up to four hours after treatment with each nebulizer. Daily peak flows were then done for 2 weeks. RESULTS: The maximal percentage of increase in FEV1 at 30 minutes using the ultrasonic nebulizer was 39.9 +/- 8% (P < 0.001) versus 25.1 +/- 7.6% (P = .005) using the jet nebulizer. There were no other differences between the ultrasonic and the jet nebulizer in FEV1 or FVC during the 4-hour spirometry. During the home trial, the difference in evening PEFR between the jet nebulizer (69.05 +/- 14.9 L/min) and the ultrasonic nebulizer (90.11 +/- 18.7 L/min) was significant (P = .04). CONCLUSIONS: In summary, the ultrasonic and the jet nebulizer produced comparable bronchodilator responses to albuterol in stable moderately to severely asthmatic patients.
    [Abstract] [Full Text] [Related] [New Search]